Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care

被引:6
|
作者
Corcoran, Anthony T. [1 ]
Smaldone, Marc C. [1 ]
Egleston, Brian L. [2 ]
Simhan, Jay [1 ]
Ginzburg, Serge [1 ]
Morgan, Todd M. [3 ]
Walton, John [1 ]
Chen, David Y. T. [1 ]
Viterbo, Rosalia [1 ]
Greenberg, Richard E. [1 ]
Uzzo, Robert G. [1 ]
Kutikov, Alexander [1 ]
机构
[1] Temple Univ, Sch Med, Fox Chase Canc Ctr, Dept Urol Oncol, Philadelphia, PA 19111 USA
[2] Temple Univ, Sch Med, Fox Chase Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA
[3] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
prostate carcinoma; screening; PSA; urological care; overdiagnosis; RADICAL PROSTATECTOMY; COMPETING RISK; URINE ASSAY; FOLLOW-UP; MORTALITY; NOMOGRAM; BIOPSY; PCA3; MEN;
D O I
10.1111/bju.12220
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate prostate cancer diagnosis rates and survival outcomes in patients receiving unrelated (non-prostate) urological care with those in patients receiving non-urological care. Materials and Methods We conducted a population-based study using the Surveillance Epidemiology and End Results (SEER) database to identify men who underwent surgical treatment of renal cell carcinoma (RCC; n = 18188) and colorectal carcinoma (CRC; n = 45093) between 1992 and 2008. Using SEER*stat software to estimate standardized incidence ratios (SIRs), we investigated rates of prostate cancer diagnosis in patients with RCC and patients with CRC. Adjusting for patient age, race and year of diagnosis on multivariate analysis, we used Cox and Fine and Gray proportional hazards regressions to evaluate overall and disease-specific survival endpoints. Results The observed incidence of prostate cancer was higher in both the patients with RCC and those with CRC: SIR = 1.36 (95% confidence interval [CI] 1.27-1.46) vs 1.06 (95% CI 1.02-1.11). Adjusted prostate cancer SIRs were 30% higher (P < 0.001) in patients with RCC. Overall (hazard ratio = 1.13, P < 0.001) and primary cancer-adjusted mortalities (sub-distribution Hazard Ratio (sHR) = 1.17, P < 0.001) were higher in patients with RCC with no significant difference in prostate cancer-specific mortality (sHR = 0.827, P = 0.391). Conclusion Rates of prostate cancer diagnosis were higher in patients with RCC (a cohort with unrelated urological cancer care) than in those with CRC. Despite higher overall mortality in patients with RCC, prostate cancer-specific survival was similar in both groups. Opportunities may exist to better target prostate cancer screening in patients who receive non-prostate-related urological care. Furthermore, urologists should not feel obligated to perform prostate-specific antigen screening for all patients receiving non-prostate-related urological care.
引用
收藏
页码:161 / 168
页数:8
相关论文
共 50 条
  • [31] Facing and avoiding urological complications of prostate cancer - Introduction
    Schulman, CC
    EUROPEAN UROLOGY, 1997, 31 : 1 - 2
  • [32] Molecular Diagnostic Trends in Urological Cancer: Biomarkers for Non-Invasive Diagnosis
    Urquidi, V.
    Rosser, C. J.
    Goodison, S.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (22) : 3653 - 3663
  • [33] RETRO-URETHRAL CATHERIZATION FOR PATIENTS WITH NON-UROLOGICAL DISORDERS - INDICATIONS, RISKS, SAFETY MEASURES
    THUROFF, JW
    PETRI, E
    JONAS, U
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1979, 104 (33) : 1157 - 1159
  • [34] A RETROSPECTIVE ANALYSIS OF VOIDING DIARY INFORMATION TO DETERMINE THE DIFFERENTIAL VOIDING PATTERN ACCORDING TO AGE AND CHEMOTHERAPY IN PATIENTS WITH NON-UROLOGICAL CANCER AND VOIDING DIFFICULTY
    Lee, H.
    Park, E.
    Kim, S.
    NEUROUROLOGY AND URODYNAMICS, 2020, 39 : S424 - S425
  • [35] A Comparison of Genitourinary Society Pathology and International Society of Urological Pathology Prostate Cancer Guidelines
    Epstein, Jonathan I.
    Kryvenko, Oleksandr N.
    EUROPEAN UROLOGY, 2021, 79 (01) : 3 - 5
  • [36] Multidisciplinary team management of patients with urological cancer
    Molokwu, C. N.
    Naqvi, T.
    Tyson, D.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2019, 80 (12) : 699 - 702
  • [37] Impact of sarcopenia in the management of urological cancer patients
    Fukushima, Hiroshi
    Koga, Fumitaka
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 455 - 466
  • [38] CHROMOCYSTOSCOPY IN THE UROLOGICAL MONITORING OF PATIENTS WITH CANCER OF THE CERVIX
    COLOMBO, M
    VITOBELLO, D
    MILANI, R
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1995, 48 (03) : 289 - 294
  • [39] Treatment of elderly patients with advanced urological cancer
    Niedersuess-Beke, Dora
    Strasser-Weippl, Kathrin
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2016, 9 (01) : 20 - 29
  • [40] Urological cancer in renal transplants patients.
    Guichard, G
    Wallerand, H
    Biftard, H
    Chalopin, JM
    Kleinclauss, F
    PROGRES EN UROLOGIE, 2006, 16 (01): : 16 - 18